Chair’s Opening Remarks
8:30 am Roundtables: Exploring Novel Technologies From Discovery Through to the Clinic to Ensure Success of Your Molecule
Synopsis
- Using predictive computational models to identify treatment responders/non-responders
- Assessing drug properties and predict pharmacokinetics, optimize formulations
- Optimizing clinical trial design • Leveraging artificial intelligence to enhance production and manufacturing of your molecule
Maximizing Novel Cytokine Approaches to Unlock New Therapeutic Potential
8:50 am Engineering Lymph-node Targeted IL-35 to Suppress Inflammation & Autoimmune Diseases
Synopsis
- Outlining challenges in production of IL-35, a strong multi-pathway anti-inflammatory cytokine
- Utilizing computational structural analyses to identify the intracellular binding site of IL35, succeeding large-scale production by mammalian cells
- Engineering lymph-node targeted IL-35, which achieves therapeutic effects in rheumatoid arthritis and directly suppresses activated immune cells
9:20 am Session reserved for Mabtech
Synopsis
9:30 am INHALAMBDA: Modulating Host Immunity in The Airways With Interferon Lambda Encoding mRNA
Synopsis
- Using Stabilised NanoParticle (SNaP) LNP platform to locally administer the drug to the lungs through inhalation or nasal spray
- Inducing an innate immune defence response in the mucosa at virus entry sites and inhibiting viral replication through extraordinarily stable lipidoid formulation of mRNDA
- Presenting preclinical results of antiviral efficacy of mRNA encoded IFN-lambda and Evaluating the safety, tolerability, and target engagement of the candidate in healthy participants for the treatment and prophylaxis of respiratory viral infections
10:00 am Rationally Engineering Synthetic CD8+ T-Cell States Endowed With the Ability to Avoid Exhaustion & Control Advanced Solid Tumors
Synopsis
- Outlining orthogonal gene engineering of T cells to secrete an interleukin (IL)-2 variant binding the IL-2Rβγ receptor and the alarmin IL-33
- Revealing that cells successfully overcame homeostatic barriers in the host and led— in the absence of lymphodepletion or exogenous cytokine support—to high levels of engraftment and tumor regression
10:30 am Networking & Morning Break
Cytokines as Combination Therapies to Improve Clinical Efficacy & Enhance Treatment Response
11:00 am Emerging Learnings From Pre-Clinical Combinations of Tumor-Activated Cytokines With Other Immune-oncology Agents
Synopsis
- Revealing the scientific rationale for using cytokines in combination
- Addressing challenges in combining systemically active cytokines
- Exploring Pre-clinical data supporting use of Xilio’s tumor-activated cytokines in combination with other IO agents
11:30 am Exploring Nemvaleukin Alfa Monotherapy & in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Synopsis
- Outlining nemvaleukin as a novel engineered cytokine
- Revealing the design to selectively bind to intermediate-affinity interleukin-2 receptor (IL-2R) for preferential activation and expansion of tumor-killing CD8+ T cells and natural
- killer (NK) cells, with minimal expansion of regulatory T cells (Tregs)
- Discussing the potential to reduce native IL-2’s toxicities, thus allowing greater tolerability and efficacy than other IL-2 molecules have shown in the past
Combining DK210 (CD20) With BiTE’s to Block Cytokine Release Syndrome
Synopsis
- Combining anti-CD19 BiTE’s in vitro dramatically enhances T cell cytolysis of tumors when combined with as low as 0.1 ng/mL BiTE concentrations
- Blunting BiTE mediated cytokine release syndrome
- Enhancing tumor responses while suppressing CRS, suggesting DK210 (tumor target) may represent a potent combination partner with BiTE platforms
12:30 pm Unleashing CD122+ Natural Killer Cell Precursors for Potent Anti-Leukemia Responses With Advanced Engineered Immunocytokine IL-2 Formulations
Synopsis
- Exploring mechanisms of immune stimulations
- Outlining PKPD data
1:00 pm Lunch Break & Networking
Supercharging Cytokine Delivery for Enhanced Specificity & Improved Efficacy
Ionizable Lipid Optimization for LNP-Mediated mRNA Delivery to Enhance Biological Performance
Synopsis
- Introducing lipid nanoparticles (LNPs) for the delivery of nucleic acids, with a focus on the role of the amino (ionizable) lipid component
- Outlining medicinal chemistry strategies for optimizing lipid/LNP physical properties, pharmacokinetics, and biological performance
- Utilizing computational modelling to guide the design of improved delivery vehicles for mRNA
2:30 pm Encapsulation of IL-12 With an Ultra pH-sensitive Tumor Delivery Platform to Improve Tolerability & Promotes Antitumor Response
Synopsis
- Overcoming narrow therapeutic indexes like IL-12 through targeted delivery
- Using ON-BOARD ultra-pH sensitive micelles to encapsulate IL-12 for safe delivery to tumor
- The ON-BOARD micelle’s tumor specificity has been clinically validated by pegsitacianine an intraoperative cancer imaging agent based on the same micelle technology
3:00 pm Developing Cell-anchored Cytokines for Immunotherapy
Synopsis
- Reviewing of cytokine anchoring strategies to ECM, biomaterials, and cells
- Uncovering mechanism of action of anchored cytokines to produce abscopal responses
- Outlining targeting approaches
3:30 pm Afternoon Break & Networking
Unlocking Novel Technologies to Transform Your Development
4:00 pm Harnessing Tissue Specific Activation of Inducible Cytokines for Treatment of Oncology and Autoimmunity
Synopsis
- Outlining Werewolf Therapeutics PREDATOR™ technology
- Exploring how technology takes advantage of protease selective linkers.
- Rendering biologically potent cytokines inactive in the periphery but allow activation in the disease target tissue of interest
4:30 pm Roundtables: Exploring Novel Technologies From Discovery Through to the Clinic to Ensure Success of Your Molecule
Synopsis
Using predictive computational models to identify treatment responders/non-responders
Assessing drug properties and predict pharmacokinetics, optimize formulations
Optimizing clinical trial design
Leveraging artificial intelligence to enhance production and manufacturing of your molecule
5:00 pm Chair’s Closing Remarks
5:10 pm End of Conference
No day selected